Jason H Peragallo1, Nancy J Newman. 1. aDepartment of Ophthalmology bDepartment of Pediatrics cDepartment of Neurology dDepartment of Neurological Surgery, Emory University, Atlanta, Georgia, USA.
Abstract
PURPOSE OF REVIEW: To discuss recent advances in potential treatments for Leber hereditary optic neuropathy (LHON), a typically visually devastating hereditary optic neuropathy caused by mutations in the mitochondrial genome. RECENT FINDINGS: Idebenone has been proposed as a means of bypassing defective complex I activity and a free radical scavenger to prevent oxidative damage. EPI-743 may have more potency than idebenone, but no clinical trials have been performed. Gene therapy techniques have advanced significantly, including allotopic expression and nuclear transfer. Successful rescue of animal models of LHON with both of these therapies has been demonstrated. Introduction of exogenous DNA into the mitochondrial genome with mitochondrial targeting of viral vectors is another promising technique. SUMMARY: There are currently no proven treatments for LHON. However, there are many promising novel treatment modalities that are currently being evaluated, with several clinical trials underway or in the planning stages. Supportive measures and genetic counseling remain of great importance for these patients.
PURPOSE OF REVIEW: To discuss recent advances in potential treatments for Leber hereditary optic neuropathy (LHON), a typically visually devastating hereditary optic neuropathy caused by mutations in the mitochondrial genome. RECENT FINDINGS:Idebenone has been proposed as a means of bypassing defective complex I activity and a free radical scavenger to prevent oxidative damage. EPI-743 may have more potency than idebenone, but no clinical trials have been performed. Gene therapy techniques have advanced significantly, including allotopic expression and nuclear transfer. Successful rescue of animal models of LHON with both of these therapies has been demonstrated. Introduction of exogenous DNA into the mitochondrial genome with mitochondrial targeting of viral vectors is another promising technique. SUMMARY: There are currently no proven treatments for LHON. However, there are many promising novel treatment modalities that are currently being evaluated, with several clinical trials underway or in the planning stages. Supportive measures and genetic counseling remain of great importance for these patients.
Authors: Hana Rauchová; Marek Vrbacký; Christian Bergamini; Romana Fato; Giorgio Lenaz; Josef Houstek; Zdenek Drahota Journal: Biochem Biophys Res Commun Date: 2005-11-14 Impact factor: 3.575
Authors: Rajeshwari Koilkonda; Hong Yu; Venu Talla; Vittorio Porciatti; William J Feuer; William W Hauswirth; Vince Chiodo; Kirsten E Erger; Sanford L Boye; Alfred S Lewin; Thomas J Conlon; Lauren Renner; Martha Neuringer; Carol Detrisac; John Guy Journal: Invest Ophthalmol Vis Sci Date: 2014-10-23 Impact factor: 4.799
Authors: Byron L Lam; William J Feuer; Joyce C Schiffman; Vittorio Porciatti; Ruth Vandenbroucke; Potyra R Rosa; Giovanni Gregori; John Guy Journal: JAMA Ophthalmol Date: 2014-04-01 Impact factor: 7.389
Authors: Matthew Anthony Kirkman; Alex Korsten; Miriam Leonhardt; Konstantin Dimitriadis; Ireneaus F De Coo; Thomas Klopstock; Philip G Griffiths; Gavin Hudson; Patrick F Chinnery; Patrick Yu-Wai-Man Journal: Invest Ophthalmol Vis Sci Date: 2009-02-28 Impact factor: 4.799
Authors: Naomi Chadderton; Arpad Palfi; Sophia Millington-Ward; Oliverio Gobbo; Nora Overlack; Matthew Carrigan; Mary O'Reilly; Matthew Campbell; Carsten Ehrhardt; Uwe Wolfrum; Peter Humphries; Paul F Kenna; G Jane Farrar Journal: Eur J Hum Genet Date: 2012-06-06 Impact factor: 4.246
Authors: Thomas Klopstock; Patrick Yu-Wai-Man; Konstantinos Dimitriadis; Jacinthe Rouleau; Suzette Heck; Maura Bailie; Alaa Atawan; Sandip Chattopadhyay; Marion Schubert; Aylin Garip; Marcus Kernt; Diana Petraki; Christian Rummey; Mika Leinonen; Günther Metz; Philip G Griffiths; Thomas Meier; Patrick F Chinnery Journal: Brain Date: 2011-07-25 Impact factor: 13.501
Authors: Matthew Anthony Kirkman; Patrick Yu-Wai-Man; Alex Korsten; Miriam Leonhardt; Konstantin Dimitriadis; Ireneaus F De Coo; Thomas Klopstock; Patrick Francis Chinnery Journal: Brain Date: 2009-06-12 Impact factor: 13.501
Authors: T Klopstock; G Metz; P Yu-Wai-Man; B Büchner; C Gallenmüller; M Bailie; N Nwali; P G Griffiths; B von Livonius; L Reznicek; J Rouleau; N Coppard; T Meier; P F Chinnery Journal: Brain Date: 2013-02-06 Impact factor: 13.501
Authors: Neringa Jurkute; Anna Majander; Richard Bowman; Marcela Votruba; Stephen Abbs; James Acheson; Guy Lenaers; Patrizia Amati-Bonneau; Mariya Moosajee; Gavin Arno; Patrick Yu-Wai-Man Journal: Eur J Hum Genet Date: 2018-08-24 Impact factor: 4.246